Clinical Trial Update: Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC [NA]

View source ↗

Summary

Clinical trial update shows the study of lenvatinib plus VIC-1911 in lenvatinib-resistant hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• VIC-1911

Snippet

Sponsor: RenJi Hospital | Conditions: Liver Cancer, Hepatocellular Carcinoma | NA | Status: TERMINATED